HIGH-DOSE IFN-ALPHA-2B VS CISPLATIN, VINBLASTINE, DTIC + IL-2 & IFN IN MELANOMA

高剂量 IFN-ALPHA-2B 与顺铂、长春碱、DTIC IL-2

• 批准号: 7607496
• 负责人: MARK R ALBERTINI
• 金额: $ 0.17万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607496
• 关键词: Cancer Cell Growth; Combination Chemotherapy; Computer Retrieval of Information on Scientific Projects Database; Dacarbazine; Dose; Drug usage; Funding; Grant; Institution; Interferon Alfa-2b; Interferon-alpha; Interferons; Interleukin-2; Leukocytes; Melanoma Cell; Patients; Persons; Phase III Clinical Trials; Randomized; Recurrence; Research; Research Personnel; Resected; Resources; Risk; Source; United States National Institutes of Health; chemotherapy; cisplatin/dacarbazine/vinblastine protocol; cisplatin/vinblastine protocol; compare effectiveness; killings; melanoma; neoplastic cell; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. [from ClinicalTrials.gov website (edited)] Interferon alfa may interfere with the growth of cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. It is not yet known whether interferon alfa given alone over 1 year is more effective than interferon alfa given with combination chemotherapy and interleukin-2 for 3 months for melanoma. This is a randomized Phase III trial to compare the effectiveness of interferon alfa with or without combination chemotherapy consisting of cisplatin, vinblastine, and dacarbazine, plus interleukin-2, in preventing recurrences in patients with resected high-risk melanoma.

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 中心，但不一定是研究者所在的机构。 [from ClinicalTrials.gov网站（编辑）] 干扰素α可能会干扰癌细胞的生长。化疗中使用的药物使用不同的方式来阻止肿瘤细胞分裂，使它们停止生长或死亡。白细胞介素-2可以刺激一个人的白色血细胞杀死黑色素瘤细胞。目前尚不清楚干扰素α单独给药1年是否比干扰素α联合化疗和白细胞介素-2治疗3个月对黑色素瘤更有效。 这是一项随机III期临床试验，旨在比较干扰素α联合或不联合顺铂、长春碱和达卡巴嗪以及白细胞介素-2组成的联合化疗预防高危黑色素瘤切除患者复发的有效性。